Richard Hopkins
Follow
Get notifications in MyBN when activity occurs.
Richard Hopkins
Outgoing Managing Director to mid May 2021 / Zelira Therapeutics
Richard Hopkins is a founder of Phylogica and had been the chief executive since July 2013; he announced his resignation in July 2016. He then became chief executive of PharmAust Pharmaceutical for a year before becoming chief executive and managing director of Zelira Therapeutics in July 2018. He will leave Zelira in mid May 2021 following a strategic consolidation by the company to have its leadership team based in the US.
His most recent research was focused on engineering peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications.
His most recent research was focused on engineering peptide leads for drug development. Dr Hopkins has published over 20 peer reviewed papers and is a co-inventor on over 10 patent applications.
Lists and Charts
Total Shareholder Return as at 26/02/21
| Rank | Company | 1 yr | 5 yr |
|---|---|---|---|
| 714th | Zelira Therapeutics | 60% | 23% |
| 1624th | Ocean Grown Abalone | -24% | |
| 1752nd | AppsVillage Australia | -45% | |
| 1762nd | Roto-Gro International | -47% | |
| 1818th | ResApp Health | -66% | -16% |
1741 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®
Powered by Morningstar ®
Roles
Year started and most recent title
Share Transactions
Total value as at the date of the transaction
Powered by Morningstar ®
Revenue
| Rank | Company | Revenue | |
|---|---|---|---|
| 137th |  | Zelira Therapeutics | $1.0m |
| 139th |  | ResApp Health | $973k |
| 140th |  | Roto-Gro International | $966k |
| 142nd | | AppsVillage Australia | $872k |
| 656th | | Ocean Grown Abalone | $4.3m |
200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Powered by Morningstar ®
Collapse All Lists and Charts
Article Timeline
Person Activity
| REMUNERATION UPDATE: Outgoing Managing Director to mid May 2021, Zelira Therapeutics | 02 Nov 2020 |
